Author:
Ryan Kimberly S.,Karpf Joshua A.,Chan Chi Ngai,Hagen Olivia L.,McFarland Trevor J.,Urian J. Wes,Wang Xiaojie,Boniface Emily R.,Hakar Melanie H.,Terrobias Jose Juanito D.,Graham Jason A.,Passmore Scarlet,Grant Kathleen A.,Sullivan Elinor L.,Grafe Marjorie R.,Saugstad Julie A.,Kroenke Christopher D.,Lo Jamie O.
Abstract
AbstractPrenatal cannabis use is associated with adverse offspring neurodevelopmental outcomes, however the underlying mechanisms are relatively unknown. We sought to determine the impact of chronic delta-9-tetrahydrocannabinol (THC) exposure on fetal neurodevelopment in a rhesus macaque model using advanced imaging combined with molecular and tissue studies. Animals were divided into two groups, control (n = 5) and THC-exposed (n = 5), which received a daily THC edible pre-conception and throughout pregnancy. Fetal T2-weighted MRI was performed at gestational days 85 (G85), G110, G135 and G155 to assess volumetric brain development. At G155, animals underwent cesarean delivery with collection of fetal cerebrospinal fluid (CSF) for microRNA (miRNA) studies and fetal tissue for histologic analysis. THC exposure was associated with significant age by sex interactions in brain growth, and differences in fetal brain histology suggestive of brain dysregulation. Two extracellular vesicle associated-miRNAs were identified in THC-exposed fetal CSF; pathway analysis suggests that these miRNAs are associated with dysregulated axonal guidance and netrin signaling. This data is indicative of subtle molecular changes consistent with the observed histological data, suggesting a potential role for fetal miRNA regulation by THC. Further studies are needed to determine whether these adverse findings correlate with long-term offspring neurodevelopmental health.
Funder
National Institutes of Health
Silver Family Foundation
Society For Maternal-Fetal Medicine
March of Dimes Foundation
Publisher
Springer Science and Business Media LLC
Reference76 articles.
1. Brown, Q. L. et al. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. Jama 317, 207–209. https://doi.org/10.1001/jama.2016.17383 (2017).
2. Obstetricians, A. C. o. & Gynecologists. Marijuana use during pregnancy and lactation. October). https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation (2017).
3. Martin, C. E., Longinaker, N., Mark, K., Chisolm, M. S. & Terplan, M. Recent trends in treatment admissions for marijuana use during pregnancy. J. Addict. Med. 9, 99–104 (2015).
4. Young-Wolff, K. C. et al. Rates of prenatal cannabis use among pregnant women before and during the COVID-19 pandemic. JAMA 326, 1745–1747 (2021).
5. Volkow, N. D., Han, B., Compton, W. M. & McCance-Katz, E. F. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. Jama 322, 167–169 (2019).